Case studies

Four examples of how we turn science into strategy and delivery.

Earlier engagement across global markets

Challenge

Stakeholders were engaged late and in a piecemeal way. Launches suffered across regions.

Approach

We designed a structured early-engagement model built around the customer, and put it in place across the product lifecycle. Functions worked to one plan and stakeholders helped shape it.

Impact

The model was rolled out across multiple affiliates worldwide. Teams were better aligned, stakeholder relationships grew stronger, and market entry was better coordinated.

A global evidence strategy for a rare disease launch

Challenge

A late-stage innovative therapy had no clear evidence priorities. That put clinical adoption and market access at risk.

Approach

We led a global, cross-functional gap analysis. We drew on international experts to set the evidence priorities.

Impact

The team had a clear, practical evidence plan. It sharpened the scientific story, supported talks with payers and improved readiness for a global launch.

Translational evidence for portfolio decisions

Challenge

The client had to make sound decisions across several assets at different stages.

Approach

We assessed each asset end to end, from preclinical evidence to clinical and real-world relevance.

Impact

The client made informed go/no-go decisions. The work supported regulatory success and found new ways to reposition and differentiate products.

Building a publication pipeline

Challenge

The client published little and had no structured evidence strategy.

Approach

We delivered a full publication strategy: systematic evidence synthesis, abstracts, and targeted journal and congress submissions.

Impact

The client quickly had a pipeline of high-quality publications. Its scientific visibility and credibility rose in its priority therapy areas.

Tell us what you’re working on

Initial discussions are confidential and without obligation. Send a short note and we will reply.

Request a call